July 11, 2026 10:29 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Foreign franchise league enters India! BBL opener to be played in Chennai, announce Modi-Albanese | 'They could have stopped me': Vijay blames police, former DMK government over Karur stampede | 'People will correct their 2025 mistake': Electoral debutant Prashant Kishor predicts BJP defeat in Bankipur | New assassination plot against Trump? Israel's secret intelligence raises alarm amid escalating Middle East tension | Ayatollah Ali Khamenei buried at Iran's holiest shrine as Middle East crisis deepens | Indian techie allegedly kills wife in US, sends photo of her body to 'secret girlfriend' in India; arrested | 'I fled the city': Thane doctor quits after alleged assault by Shiv Sena leader | Sensex surges 500 points before losing steam, ends marginally higher after volatile trading session | US court drops charges against Indian-origin doctor who drove Tesla off 250-foot cliff with family | Dalal Street bleeds! Sensex tanks over 1,600 points after Trump declares Iran ceasefire 'over'
Image: UNI

MSN Labs launches Posaconazole to treat Black Fungus

| @indiablooms | May 22, 2021, at 12:25 am

Kolkata/IBNS: Drugmaker MSN Laboratories Pvt. Ltd. (MSN) on Friday introduced Posaconazole under the brand name PosaOne, a triazole antifungal agent, for treating mucormycosis or Black Fungus in patients, especially those recovering from Covid19. 

PosaOne contains both 100 mg delayed-release tablets & 300 mg injections.

While the price of the tablet is Rs 600, the injections cost a staggering Rs 8,500, according to The Hindu.

Many patients recovering from Covid 19 have been detected with a rare and deadly fungal infection known as mucormycosis or Black fungus. With mortality rates on the rise, accessibility of anti-fungal medication is being an unmet deficit in these testing times, MSN said.

The company officials said that due to MSN’s competence in research and manufacturing of antifungal infection drugs, it is now targeting proactively to reach patients across India by ensuring the access of PosaOne, through its distribution network & field force.

MSN has also developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units, company personnel informed, while also stating that the drug is approved by the Drug Controller General of India (DGCI) and matches the international quality standards.

As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules, recently, it also licensed Baridoz (Baricitinib) with Eli Lilly, MSN stated.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.